Takeda has reported positive results from a phase 3 trial of its experimental therapy TAK-755 for ultra-rare disease congenital thrombotic thrombocytopenic purpura (cTTP), setting up regula
More than 30 years after it was first formed, Geron is on the cusp of bringing its first product to market, after imetelstat hit the mark in a phase 3 trial in patients with myelodysplastic
The final day of the ASH congress always includes a session on late-breaking studies, and this year was no exception, with presentations on Novartis' iptacopan in paroxysmal nocturnal haemo
Dutch biotech Argenx is on course to add another rare disease indication to the label of its FcRn blocker Vyvgart – for primary immune thrombocytopenia (ITP) – thanks to new data reported a
Johnson & Johnson is in pole position to bring a drug targeting GPRC5D to market as a new therapeutic approach to multiple myeloma, and told delegates at ASH yesterday why its talquetam
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.
